001     165377
005     20240826165948.0
024 7 _ |a pmc:PMC10151179
|2 pmc
024 7 _ |a 10.1093/brain/awac385
|2 doi
024 7 _ |a pmid:36288546
|2 pmid
024 7 _ |a 0006-8950
|2 ISSN
024 7 _ |a 1460-2156
|2 ISSN
024 7 _ |a altmetric:137724675
|2 altmetric
037 _ _ |a DZNE-2022-01651
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Nemy, Milan
|0 0000-0002-4870-1354
|b 0
245 _ _ |a Cholinergic white matter pathways along the Alzheimer's disease continuum.
260 _ _ |a Oxford
|c 2023
|b Oxford Univ. Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1709567093_22643
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Previous studies have shown that the cholinergic nucleus basalis of Meynert and its white matter projections are affected in Alzheimer's disease dementia and mild cognitive impairment. However, it is still unknown whether these alterations can be found in individuals with subjective cognitive decline, and whether they are more pronounced than changes found in conventional brain volumetric measurements. To address these questions, we investigated microstructural alterations of two major cholinergic pathways in individuals along the Alzheimer's disease continuum using an in vivo model of the human cholinergic system based on neuroimaging. We included 402 participants (52 Alzheimer's disease, 66 mild cognitive impairment, 172 subjective cognitive decline and 112 healthy controls) from the Deutsches Zentrum für Neurodegenerative Erkrankungen Longitudinal Cognitive Impairment and Dementia Study. We modelled the cholinergic white matter pathways with an enhanced diffusion neuroimaging pipeline that included probabilistic fibre-tracking methods and prior anatomical knowledge. The integrity of the cholinergic white matter pathways was compared between stages of the Alzheimer's disease continuum, in the whole cohort and in a CSF amyloid-beta stratified subsample. The discriminative power of the integrity of the pathways was compared to the conventional volumetric measures of hippocampus and nucleus basalis of Meynert, using a receiver operating characteristics analysis. A multivariate model was used to investigate the role of these pathways in relation to cognitive performance. We found that the integrity of the cholinergic white matter pathways was significantly reduced in all stages of the Alzheimer's disease continuum, including individuals with subjective cognitive decline. The differences involved posterior cholinergic white matter in the subjective cognitive decline stage and extended to anterior frontal white matter in mild cognitive impairment and Alzheimer's disease dementia stages. Both cholinergic pathways and conventional volumetric measures showed higher predictive power in the more advanced stages of the disease, i.e. mild cognitive impairment and Alzheimer's disease dementia. In contrast, the integrity of cholinergic pathways was more informative in distinguishing subjective cognitive decline from healthy controls, as compared with the volumetric measures. The multivariate model revealed a moderate contribution of the cholinergic white matter pathways but not of volumetric measures towards memory tests in the subjective cognitive decline and mild cognitive impairment stages. In conclusion, we demonstrated that cholinergic white matter pathways are altered already in subjective cognitive decline individuals, preceding the more widespread alterations found in mild cognitive impairment and Alzheimer's disease. The integrity of the cholinergic pathways identified the early stages of Alzheimer's disease better than conventional volumetric measures such as hippocampal volume or volume of cholinergic nucleus basalis of Meynert.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 1
536 _ _ |a 351 - Brain Function (POF4-351)
|0 G:(DE-HGF)POF4-351
|c POF4-351
|f POF IV
|x 2
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Alzheimer Disease: psychology
|2 MeSH
650 _ 2 |a White Matter
|2 MeSH
650 _ 2 |a Brain
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: psychology
|2 MeSH
650 _ 2 |a Cholinergic Agents
|2 MeSH
650 _ 7 |a Alzheimer’s disease
|2 Other
650 _ 7 |a Alzheimer’s disease
|2 Other
650 _ 7 |a Alzheimer’s disease
|2 Other
650 _ 7 |a cerebrospinal fluid markers
|2 Other
650 _ 7 |a cholinergic system
|2 Other
650 _ 7 |a magnetic resonance imaging
|2 Other
650 _ 7 |a nucleus basalis of Meynert
|2 Other
650 _ 7 |a CSF markers
|2 Other
650 _ 7 |a MRI
|2 Other
650 _ 7 |a Cholinergic Agents
|2 NLM Chemicals
693 _ _ |0 EXP:(DE-2719)DELCODE-20140101
|5 EXP:(DE-2719)DELCODE-20140101
|e Longitudinal Cognitive Impairment and Dementia Study
|x 0
700 1 _ |a Dyrba, Martin
|0 P:(DE-2719)2810283
|b 1
|u dzne
700 1 _ |a Brosseron, Frederic
|0 P:(DE-2719)2810593
|b 2
|u dzne
700 1 _ |a Bürger, Katharina
|0 P:(DE-2719)2811351
|b 3
|u dzne
700 1 _ |a Dechent, Peter
|b 4
700 1 _ |a Dobisch, Laura
|0 P:(DE-2719)2811611
|b 5
|u dzne
700 1 _ |a Ewers, Michael
|0 P:(DE-2719)9000543
|b 6
|u dzne
700 1 _ |a Fliessbach, Klaus
|0 P:(DE-2719)2811326
|b 7
|u dzne
700 1 _ |a Glanz, Wenzel
|0 P:(DE-2719)2811614
|b 8
|u dzne
700 1 _ |a Görß, Doreen
|0 P:(DE-2719)2812583
|b 9
|u dzne
700 1 _ |a Heneka, Michael T
|0 P:(DE-2719)2000008
|b 10
|u dzne
700 1 _ |a Hetzer, Stefan
|b 11
700 1 _ |a Incesoy, Enise I
|0 P:(DE-2719)9001517
|b 12
|u dzne
700 1 _ |a Janowitz, Daniel
|b 13
700 1 _ |a Kilimann, Ingo
|0 P:(DE-2719)2810394
|b 14
|u dzne
700 1 _ |a Laske, Christoph
|0 P:(DE-2719)2000055
|b 15
|u dzne
700 1 _ |a Maier, Franziska
|b 16
700 1 _ |a Munk, Matthias H
|0 P:(DE-2719)9001516
|b 17
|u dzne
700 1 _ |a Perneczky, Robert
|0 P:(DE-2719)2812234
|b 18
|u dzne
700 1 _ |a Peters, Oliver
|0 P:(DE-2719)2811024
|b 19
|u dzne
700 1 _ |a Preis, Lukas
|0 P:(DE-2719)9000703
|b 20
|u dzne
700 1 _ |a Priller, Josef
|0 P:(DE-2719)2811122
|b 21
|u dzne
700 1 _ |a Rauchmann, Boris Stephan
|0 P:(DE-2719)9001808
|b 22
|u dzne
700 1 _ |a Röske, Sandra
|0 P:(DE-2719)2810395
|b 23
|u dzne
700 1 _ |a Roy, Nina
|0 P:(DE-2719)2812341
|b 24
|u dzne
700 1 _ |a Scheffler, Klaus
|b 25
700 1 _ |a Schneider, Anja
|0 P:(DE-2719)2812035
|b 26
|u dzne
700 1 _ |a Schott, Björn
|0 P:(DE-2719)2814326
|b 27
|u dzne
700 1 _ |a Spottke, Annika
|0 P:(DE-2719)2811324
|b 28
|u dzne
700 1 _ |a Spruth, Eike J
|0 P:(DE-2719)2812446
|b 29
|u dzne
700 1 _ |a Wagner, Michael
|0 P:(DE-2719)2000057
|b 30
|u dzne
700 1 _ |a Wiltfang, Jens
|0 P:(DE-2719)2811317
|b 31
|u dzne
700 1 _ |a Yakupov, Renat
|0 P:(DE-2719)2812398
|b 32
|u dzne
700 1 _ |a Eriksdotter, Maria
|b 33
700 1 _ |a Westman, Erik
|0 0000-0002-3115-2977
|b 34
700 1 _ |a Stepankova, Olga
|b 35
700 1 _ |a Vyslouzilova, Lenka
|b 36
700 1 _ |a Düzel, Emrah
|0 P:(DE-2719)2000005
|b 37
|u dzne
700 1 _ |a Jessen, Frank
|0 P:(DE-2719)2000032
|b 38
|u dzne
700 1 _ |a Teipel, Stefan J
|0 P:(DE-2719)2000026
|b 39
|u dzne
700 1 _ |a Ferreira, Daniel
|b 40
773 _ _ |a 10.1093/brain/awac385
|g p. awac385
|0 PERI:(DE-600)1474117-9
|n 5
|p 2075-2088
|t Brain
|v 146
|y 2023
|x 0006-8950
856 4 _ |u https://pub.dzne.de/record/165377/files/DZNE-2022-01651%20SUP.pdf
856 4 _ |u https://pub.dzne.de/record/165377/files/DZNE-2022-01651%20SUP.pdf?subformat=pdfa
|x pdfa
856 4 _ |u https://pub.dzne.de/record/165377/files/DZNE-2022-01651.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/165377/files/DZNE-2022-01651.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:165377
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2810283
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2810593
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)2811351
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2811611
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)9000543
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2811326
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2811614
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2812583
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2000008
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)9001517
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)2810394
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 15
|6 P:(DE-2719)2000055
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 17
|6 P:(DE-2719)9001516
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 18
|6 P:(DE-2719)2812234
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 19
|6 P:(DE-2719)2811024
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 20
|6 P:(DE-2719)9000703
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 21
|6 P:(DE-2719)2811122
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 22
|6 P:(DE-2719)9001808
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 23
|6 P:(DE-2719)2810395
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 24
|6 P:(DE-2719)2812341
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 26
|6 P:(DE-2719)2812035
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 27
|6 P:(DE-2719)2814326
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 28
|6 P:(DE-2719)2811324
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 29
|6 P:(DE-2719)2812446
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 30
|6 P:(DE-2719)2000057
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 31
|6 P:(DE-2719)2811317
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 32
|6 P:(DE-2719)2812398
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 37
|6 P:(DE-2719)2000005
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 38
|6 P:(DE-2719)2000032
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 39
|6 P:(DE-2719)2000026
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 1
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-351
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Brain Function
|x 2
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-29
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0
|0 LIC:(DE-HGF)CCBYNC4
|2 HGFVOC
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-29
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-10-21
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-21
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BRAIN : 2022
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-21
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-21
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b BRAIN : 2022
|d 2023-10-21
920 1 _ |0 I:(DE-2719)1510100
|k AG Teipel
|l Clinical Dementia Research (Rostock /Greifswald)
|x 0
920 1 _ |0 I:(DE-2719)1011301
|k Biomarker
|l Interventional Trials and Biomarkers in Neurodegenerative Diseases
|x 1
920 1 _ |0 I:(DE-2719)5000022
|k AG Dichgans
|l Vascular Cognitive Impairment & Post-Stroke Dementia
|x 2
920 1 _ |0 I:(DE-2719)1340009
|k AG Speck
|l Linking imaging projects iNET
|x 3
920 1 _ |0 I:(DE-2719)1110008
|k AG Simons
|l Molecular Neurobiology
|x 4
920 1 _ |0 I:(DE-2719)1011101
|k Patient Studies Bonn
|l Patient Studies Bonn
|x 5
920 1 _ |0 I:(DE-2719)5000006
|k AG Düzel
|l Clinical Neurophysiology and Memory
|x 6
920 1 _ |0 I:(DE-2719)1340013
|k KAP
|l Cooperation Unit for Applied Prevention Research (KAP)
|x 7
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 8
920 1 _ |0 I:(DE-2719)5000007
|k AG Priller
|l Translational Neuropsychiatry
|x 9
920 1 _ |0 I:(DE-2719)1011201
|k AG Wagner
|l Neuropsychology
|x 10
920 1 _ |0 I:(DE-2719)1011401
|k Clinical Research Platform (CRP)
|l Clinical Research Platform (CRP)
|x 11
920 1 _ |0 I:(DE-2719)1011305
|k AG Schneider
|l Translational Dementia Research (Bonn)
|x 12
920 1 _ |0 I:(DE-2719)1410002
|k AG Fischer
|l Epigenetics and Systems Medicine in Neurodegenerative Diseases
|x 13
920 1 _ |0 I:(DE-2719)1011102
|k AG Jessen
|l Clinical Alzheimer’s Disease Research
|x 14
920 1 _ |0 I:(DE-2719)1811005
|k AG Endres
|l Interdisciplinary Dementia Research
|x 15
920 1 _ |0 I:(DE-2719)1410006
|k AG Wiltfang
|l Molecular biomarkers for predictive diagnostics of neurodegenerative diseases
|x 16
920 1 _ |0 I:(DE-2719)5000034
|k Delcode
|l Delcode
|x 17
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1510100
980 _ _ |a I:(DE-2719)1011301
980 _ _ |a I:(DE-2719)5000022
980 _ _ |a I:(DE-2719)1340009
980 _ _ |a I:(DE-2719)1110008
980 _ _ |a I:(DE-2719)1011101
980 _ _ |a I:(DE-2719)5000006
980 _ _ |a I:(DE-2719)1340013
980 _ _ |a I:(DE-2719)1210000
980 _ _ |a I:(DE-2719)5000007
980 _ _ |a I:(DE-2719)1011201
980 _ _ |a I:(DE-2719)1011401
980 _ _ |a I:(DE-2719)1011305
980 _ _ |a I:(DE-2719)1410002
980 _ _ |a I:(DE-2719)1011102
980 _ _ |a I:(DE-2719)1811005
980 _ _ |a I:(DE-2719)1410006
980 _ _ |a I:(DE-2719)5000034
980 _ _ |a UNRESTRICTED
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21